Patent filed for novel orexin 1 antagonist programme

A patent application for our novel orexin 1 antagonist has been filed on 1 September 2017. This is an entirely new composition of matter patent supporting our binge eating disorder and alcohol use disorder programmes.

Contact Us

Want to get in touch? Send us an email.

Not readable? Change text. captcha txt